Drug Profile
Cannabidiol/dronabinol- Beckley Canopy Therapeutics
Alternative Names: BCT-521Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Beckley Canopy Therapeutics
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cancer pain
- No development reported Unspecified
Most Recent Events
- 28 May 2021 No recent reports of development identified for clinical-Phase-Unknown development in Unspecified in United Kingdom (PO)
- 26 Aug 2020 Beckley Canopy Therapeutics completes a phase I/II trials in Cancer pain in Poland (PO, Capsule) (EudraCT2019-001382-32)
- 26 Nov 2019 Phase-I/II clinical trials in Cancer pain in Poland (PO, Capsule) (EudraCT2019-001382-32)